Compare FMC Corp (FMC) vs NICE Ltd (NICE) Price & Performance

FMC Corporation (FMC) trades at $11.61, up 8.3% today, but remains in a challenging fundamental position with a net income margin of -72.93% and negative ROE of -80.78% for 2025. The company is actively restructuring, securing a $400 million minority investment from Tessenderlo Group and planning a $114 million property sale to reduce its $3.03 billion long-term debt. Technical indicators are bearish, with the stock trading near key support at $11. Recent news highlights progress on its new herbicide, rimisoxafen, including a regulatory submission to the EPA and a partnership with Corteva.

The outlook is cautious. While aggressive debt reduction and new product pipelines offer potential, deep losses and declining revenue pose significant risks. The analyst consensus is mixed (47.6% Buy, 50% Hold) with a $16 price target, suggesting modest upside if turnaround efforts succeed, but high execution risk remains the primary concern for investors.

NICE trades at $101.35, down 0.91% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.64 surpassing the $2.52 estimate. Fundamentals show robust profitability with a 65.79% gross margin and 17.57% net income margin. Recent news highlights AI-driven customer engagement expansions, including partnerships with Banco do Brasil and Sopra Steria.

The outlook remains positive with a consensus price target of $124.88, implying 23% upside. Risks include competitive pressures in AI software and potential margin compression. Analyst sentiment is bullish with 13 buys and no sells among 23 coverage firms, though technical indicators suggest near-term overbought conditions may limit immediate gains.